A practical reference on incretin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-31. Anything still debated is marked as such rather than presented as settled.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
== Amino acid profile == Hemp protein is rich in essential amino acids, containing, in sufficient quantities, all essential amino acids required by humans except lysine, which appears at lower than recommended levels for infants aged up to five years old according to Food and agricultural organization (FOA) standards; still, the overall nutritive value of hemp protein remains relatively good, as sulfur-containing amino acids are higher than in casein or soy, while other non-essential amino acids present in hemp protein, such as arginine, provide additional health benefits including cardiovascular support, immune function optimization, and muscle repair. Hemp protein has unique properties that are useful in food processing. Its cysteine-rich amino acid composition and high sulfhydryl (-SH)/disulfide (S-S) ratio offer a glimpse of its distinctive features. These features can facilitate the development of new food materials.
{\displaystyle {\begin{aligned}u(y,z)&={\frac {G}{2\mu }}y(h-y)-{\frac {4Gh^{2}}{\mu \pi ^{3}}}\sum _{n=1}^{\infty }{\frac {1}{(2n-1)^{3}}}{\frac {\sinh(\beta _{n}z)+\sinh[\beta _{n}(l-z)]}{\sinh(\beta _{n}l)}}\sin(\beta _{n}y),\quad \beta _{n}={\frac {(2n-1)\pi }{h}},\\[6pt]Q&={\frac {Gh^{3}l}{12\mu }}-{\frac {16Gh^{4}}{\pi ^{5}\mu }}\sum _{n=1}^{\infty }{\frac {1}{(2n-1)^{5}}}{\frac {\cosh(\beta _{n}l)-1}{\sinh(\beta _{n}l)}}.\end{aligned}}}
Red blood cells are used to restore oxygen-carrying capacity in people with anaemia due to trauma or other medical problems Whenever a red blood cell transfusion is being considered for a patient, it is good practice to consider not only the haemoglobin level, but also the overall clinical context, patient preferences, and whether there are alternative treatments. If a patient is stable and has a haematinic deficiency, they should be treated for the deficiency (iron deficiency, B12 deficiency, or folate deficiency) rather than being given a red blood cell transfusion. In adults, blood transfusion is typically recommended when hemoglobin levels are below 70 g/L (7 g/dL) in those who have stable vital signs, unless they have anemia due to a haematinic deficiency. Transfusing at a restrictive haemoglobin threshold of between 70 g/L to 80 g/L (7 to 8g/dL) decreased the proportion of people given a red blood cell transfusion by 41% across a broad range of clinical specialties, including those people who are critically ill. There is no evidence that a restrictive transfusion strategy are stronger associated with death or major adverse events (e.g. cardiac events, myocardial infarction, stroke, pneumonia, thromboembolism, infection) compared with a liberal transfusion strategy. There is not enough information in some patient groups to say whether a restrictive or liberal transfusion threshold is better.
=== Food-induced dose dumping (FIDD) === Food intake produces dynamic changes in digestion and pharmacokinetics through a variety of mechanisms, which can produce an unintended release of modified-release dosages under certain circumstances. Usually, high fat diets are the most associated with this phenomenon, but there is evidence that standard-composition food can cause this even in immediate release formulations, such as the case of methylphenidate. Some of the mechanisms involved in FIDD are:
Sources: en.wikipedia.org
After the 2020 presidential election, Kennedy and 11 other Republican senators said they would object to certain states' electoral votes in the 2021 United States Electoral College vote count on January 6, 2021, unless the vote was audited. He was participating in the certification when Trump supporters stormed the United States Capitol. Kennedy called the attack "despicable and shameful" and called for the rioters "to go to jail and pay for the destruction they caused." When the Capitol was secured and Congress returned to complete the certification, he objected to the certification of Arizona's electoral votes. On February 9, 2021, Kennedy voted against Trump's second impeachment. Kennedy said the impeachment effort was unconstitutional because Trump was no longer president. He called the impeachment process "a thinly veiled effort by the uber-elites in our country, who look down on most Americans, to denigrate further those people who chose to vote for President Trump and not vote for President Biden." On March 6, 2021, Kennedy voted against the American Rescue Plan Act of 2021, a COVID-19 recovery package. He said he voted against it because it was "an orgy of pork", adding, "This is not a coronavirus bill, not the way it's been portrayed". On May 28, 2021, Kennedy voted against the January 6 commission House Speaker Nancy Pelosi proposed to investigate the January 6 attack. The commission failed to gain traction, but the House later successfully established the January 6 committee as an alternative.
== Structure == While an Army unit, the Selous Scouts came under the operational control of Special Branch from its establishment in November 1973. This involved Special Branch controlling where the unit operated and how the intelligence it collected was used. Special Branch also had some influence over the Selous Scouts' training. In terms of Army hierarchy, the Selous Scouts reported directly to Walls. The unit was under orders from Special Branch to not pass any information directly to the Rhodesian Directorate of Military Intelligence, which contributed to very little of the intelligence it collected being provided to Army units. The Selous Scouts and other Rhodesian special forces continued to report directly to Walls for military purposes after he became the Commander of Combined Operations (COMOPS) in 1977. The Army headquarters provided administrative and logistical support. As the Selous Scouts increased in size and increasingly undertook offensive operations it became impossible for Special Branch to adequately oversee the unit. Each troop within the Selous Scouts comprised three sections, each usually with nine to twelve men. The size of sections varied, however, and could be as large as 30 men. Selous Scout teams usually included both black and white personnel, with the men forming close bonds. Until almost the end of the war, all of the officers in the Selous Scouts were white.
== Function == The α-macroglobulin (αM) family of proteins includes protease inhibitors, typified by the human tetrameric α2-macroglobulin (α2M); they belong to the MEROPS proteinase inhibitor family I39, clan IL. These protease inhibitors share several defining properties, which include (1) the ability to inhibit proteases from all catalytic classes, (2) the presence of a 'bait region' (also known as a sequence of amino acids in an α2-macroglobulin molecule, or a homologous protein, that contains scissile peptide bonds for those proteinases that it inhibits) and a thiol ester, (3) a similar protease inhibitory mechanism and (4) the inactivation of the inhibitory capacity by reaction of the thiol ester with small primary amines. αM protease inhibitors inhibit by steric hindrance. The mechanism involves protease cleavage of the bait region, a segment of the αM that is particularly susceptible to proteolytic cleavage, which initiates a conformational change such that the αM collapses about the protease. In the resulting αM-protease complex, the active site of the protease is sterically shielded, thus substantially decreasing access to protein substrates. Two additional events occur as a consequence of bait region cleavage, namely (1) the h-cysteinyl-g-glutamyl thiol ester becomes highly reactive and (2) a major conformational change exposes a conserved COOH-terminal receptor binding domain (RBD). RBD exposure allows the αM protease complex to bind to clearance receptors and be removed from circulation.
study done in 2000 had different results which found that many fewer children responded as being abused by a stepparent. Economic factors could also play a role in the abuse of stepchildren. In places with higher levels of social strain, abuse may be more prevalent or more violent. Other studies of census data and child neglect and abuse records have found that stepparents may be over-represented in abuse figures. They have found that when the data is balanced, biological parents have a much higher rate of abuse than stepparents do. There is little research in the field of parental abuse by children in concern with stepchildren abusing stepparents. The abuse of stepchildren by their siblings is also a topic with little research.
An international consortium of researchers from 10 countries began sequencing the tomato genome in 2004. A prerelease version of the genome was made available in December 2009. The complete genome for the cultivar Heinz 1706 was published on 31 May 2012 in Nature. The latest reference genome published in 2021 had 799 MB and encodes 34,384 (predicted) proteins, spread over 12 chromosomes. The first commercially available genetically modified food was a tomato called Flavr Savr, which was engineered to have a longer shelf life. It could be vine ripened without compromising shelf life, which was expected to improve the flavor over ethylene-ripened tomatoes. However, it was not firmer than its unmodified parent, to the disappointment of its creators, who originally wanted to create a vine-ripened tomato that could survive machine-picking. The parent variety was also subpar in terms of yields. As a result, the product was not commercially successful, and was sold only until 1997. When the Mesoamericans domesticated tomatoes, they selected for less bitter fruits. This corresponded to the increased activity of a 2-oxoglutarate-dependent dioxygenase called 23DOX (synonym GAME31) during fruit ripening, which converts the bitter and slightly toxic α-tomatine into hydroxytomatine, which is eventually converted into the non-bitter and non-toxic esculeoside A.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。